Incyte Corporation (INCY)vsMerck & Company Inc (MRK)
INCY
Incyte Corporation
$95.27
-3.86%
HEALTHCARE · Cap: $19.80B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1113% more annual revenue ($65.01B vs $5.36B). MRK leads profitability with a 28.1% profit margin vs 26.7%. INCY appears more attractively valued with a PEG of 0.35. INCY earns a higher WallStSmart Score of 83/100 (A-).
INCY
Exceptional Buy83
out of 100
Grade: A-
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.2%
Fair Value
$624.90
Current Price
$95.27
$529.63 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 31 in profit
Earnings expanding 83.8% YoY
Safe zone — low bankruptcy risk
Keeps 27 of every $100 in revenue as profit
Attractively priced relative to earnings
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
No major concerns identified
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 26.7% and operating margin at 25.5%. Revenue growth of 20.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
INCY profiles as a growth stock while MRK is a value play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.86 — expect wider price swings.
INCY is growing revenue faster at 20.9% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
INCY scores higher overall (83/100 vs 59/100), backed by strong 26.7% margins and 20.9% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?